Vaccine
Syvazul® BTV suspension for injection
Inactivated vaccine against bluetongue as suspension for injection
(Serotipos 1, 4 u 8 o una combinación de dos de ellos)
The information available on this page complies with the legislation and texts in vigour in Spain. For all other countries, please refer to the specific local information or contact our Export Department for more information.
*The content of this page is purely informative. For a correct use of the products, please refer to the indications in the Summary of product characteristics..
Quick product information
| Active ingredient(s) | Posology* | Waiting time | Packaging |
|---|---|---|---|
Inactivated Bluetongue Virus Serotype 1 (BTV-1), serotype 4 (BTV-4), serotype 8 (BTV-8) | Sheep: subcutaneous administration | Zero days | 80 ml 200 ml |
Country Availability
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Spain, Sweden, United Kingdom.
If your country is not listed, please contact our export team.
Active ingredient(s)
Inactivated bluetongue virus (BTV) RP** ≥ 1
* Maximum of two different inactivated bluetongue virus serotypes:
Inactivated Bluetongue Virus Serotype 1 (BTV-1), strain ALG2006/01 E1
Inactivated Bluetongue Virus Serotype 4 (BTV-4), strain BTV-4/SPA-1/2004
Inactivated Bluetongue Virus, Serotype 8 (BTV-8), strain BEL2006/01
**Relative potency determined by ELISA in relation to a reference vaccine whose efficacy has been demonstrated by challenge in the target species.
The number and type of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label.
Indications
Sheep:
Active immunisation of sheep to prevent viraemia* and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/or 8, or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4 (combination of up to 2 serotypes).
*Below the level of detection by the validated RT-PCR method at 1.32 log10 TCID50/ml
Onset of immunity: 39 days after completion of the primary vaccination scheme.
Duration of immunity: one year after completion of the primary vaccination scheme.
Cattle:
For active immunisation of cattle to prevent viraemia* caused by serotypes 1 and/or 8 of the blue tonguevirus and to reduce viraemia* caused by bluetongue virus serotype 4 (combination of maximum 2 serotypes).
*Below the level of detection by the validated RT-PCR method at 1.32 log10 TCID50/ml
Onset of immunity: 21 days after completion of the primary vaccination scheme.
Duration of immunity: one year after completion of the primary vaccination scheme.
Special precautions
Specific precautions to be taken by the person administering the veterinary medicinal product to
animals:
In case of accidental self-injection, consult a doctor immediately and show them the package leaflet.
or the label.
Individuals with known hypersensitivity to aluminium hydroxide, thiomersal or saponins should avoid all contact with the veterinary medicinal product.
Posology
Shake well before use.
Sheep:
Subcutaneous administration.
Administer subcutaneously to sheep from 3 months of age, according to the following schedule:
– Primary vaccination: administer a single 2 ml dose.
– Revaccination: administer one dose of 2 ml after 12 months.
Cattle:
Intramuscular administration.
Administer intramuscularly to cattle from 2 months of age in animals not treated previously or from 3 months of age in calves born to immunised cattle, according to the following schedule:
-Primary vaccination: administer two doses of 4 ml 3 weeks apart.
– Revaccination: administer one dose of 4 ml after 12 months.
Waiting time
Zero days.
Packaging
Containers with 80 and 200 ml.
With veterinary prescription.
Registry no.: EU/2/18/231/001-012
